{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.4"},{"groupId":"OG001","value":"66.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"153"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"CBR was defined as the percentage of participants achieving a MR or better as BOR. MR was defined as \\>= 25% but \\<= 49% reduction in serum M-protein and reduction in 24h urine M-protein by 50-89%, which still exceed 200 mg/24h; if present at baseline, \\>=50% reduction in size (SPD) of soft tissue plasmacytomas was also required. BOR was defined as the best sequential response, using the IRC's assessment of response, from the start of treatment until disease progression (provided that the progression is subsequently confirmed in case of progression requiring confirmation), death, initiation of further anti-myeloma treatment, or cut-off date, whichever occurs first.","groups":[{"description":"Participants received pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle plus dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone) PO on Days 1, 8, 15 and 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 73.7 weeks).","id":"OG000","title":"Pd (Pomalidomide + Dexamethasone)"},{"description":"Participants received isatuximab 10 mg/kg IV infusion on Days 1, 8, 15, and 22 at Cycle 1, and then on Days 1 and 15 of subsequent cycles plus pomalidomide 4 mg PO on Days 1 to 21 of each 28-day treatment cycle and dexamethasone 40 mg (participants \\>= 75 years of age received 20 mg dexamethasone), PO or IV on Day 1, 8, 15, 22 of each 28-day treatment cycle until disease progression or unacceptable toxicity or participant's wish to discontinue study treatment, or any other reason, whichever comes first (maximum exposure: 76.7 weeks).","id":"OG001","title":"IPd (Isatuximab + Pomalidomide + Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population.","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of first documentation of progression, death, initiation of further anti-myeloma treatment or data cut-off whichever comes first (maximum duration 76.7 weeks)","title":"Clinical Benefit Rate (CBR): Percentage of Participants With Clinical Benefit as Per Independent Response Committee","type":"SECONDARY","unitOfMeasure":"percentage of participants"}